Annals of Surgical Oncology

, 18:3129 | Cite as

Perceptions of Contralateral Breast Cancer: An Overestimation of Risk

  • Andrea Abbott
  • Natasha Rueth
  • Susan Pappas-Varco
  • Karen Kuntz
  • Elizabeth Kerr
  • Todd Tuttle
American Society of Breast Surgeons

Abstract

Introduction

The rate of contralateral prophylactic mastectomy (CPM) has recently increased. The aim of this study is to assess perceptions of contralateral breast cancer (CBC) risk among breast cancer patients and to evaluate tumor and patient factors associated with risk perception.

Methods

We conducted a prospective survey study to evaluate perceptions of CBC risk in women newly diagnosed with ductal carcinoma in situ (DCIS) or stage I/II invasive breast cancer. Surveys were distributed in clinic prior to surgical consultation. Exclusion criteria included history of breast cancer, bilateral breast cancer, neoadjuvant chemotherapy or radiation for the current breast cancer, or BRCA mutation. Survey questions used open-ended responses or five-point Likert scale scoring (5 = very likely, 1 = not at all likely).

Results

Seventy-four women (mean age 54.5 years) completed the survey. Diagnoses included invasive ductal cancer (66.2%), invasive lobular cancer (9.5%), and DCIS (20.3%). Most women (54.1%) underwent breast-conserving surgery; the remaining had bilateral mastectomy including CPM (17.6%) or unilateral mastectomy (10.8%). Overall, women substantially overestimated their risk of developing CBC. The mean estimated 10-year risk of CBC was 31.4% [95% confidence interval (CI) 24.7–37.9%] and 2.6 ± 0.15 on the rank scale. The perceived risk of CBC was not significantly associated with cancer stage, family history, age, or CPM.

Conclusions

At time of surgical evaluation, women with unilateral breast cancer substantially overestimated their risk of CBC; however, this elevated risk perception was not associated with choosing CPM. Early physician counseling is needed to provide women with accurate information regarding their true CBC risk.

References

  1. 1.
    Harvey EB, Brinton LA. Second cancer following cancer of the breast in Connecticut, 1935-82. Natl Cancer Inst Monogr. 1985;68:99–112.PubMedGoogle Scholar
  2. 2.
    Gao X, Fisher SG, Emami B. Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int J Radiat Oncol Biol Phys. 2003;56:1038–45.PubMedCrossRefGoogle Scholar
  3. 3.
    Nichols HB, Berrington de Gonzalez A, Lacey JV Jr, Rosenberg PS, Anderson WF. Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J Clin Oncol. doi:10.1200/JCO.2010.32.7395 (online March 14 2011).
  4. 4.
    Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC Trial. Lancet. 2010;11:1135–41.CrossRefGoogle Scholar
  5. 5.
    Tuttle TM, Habermann EB, Grund EH, et al. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol. 2007;25:5203–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Tuttle TM, Jarosek S, Habermann EB, et al. Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. J Clin Oncol. 2009;27:1362–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Rakovitch E, Franssen E, Kim J, et al. A comparison of risk perception and psychological morbidity in women with ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res Treat. 2003;77:285–93.PubMedCrossRefGoogle Scholar
  8. 8.
    Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004;22:2328–35.PubMedCrossRefGoogle Scholar
  9. 9.
    McLaughlin CC, Lillquist PP, Edge SB. Surveillance of prophylactic mastectomy. Trends in use from 1995 through 2005. Cancer. 2009;115:5404–12.PubMedCrossRefGoogle Scholar
  10. 10.
    Sobrero ME, Dick AW, Beckjord EB, et al. Diagnostic breast magnetic resonance imaging and contralateral prophylactic mastectomy. Ann Surg Oncol. 2009;16:1597–605.CrossRefGoogle Scholar
  11. 11.
    Jones NB, Wilson J, Kotur L, Stephens J, Farrar WB, Agnese DM. Contralateral prophylactic mastectomy for unilateral breast cancer: an increasing trend at a single institution. Ann Surg Oncol. 2009;16:2691–96.PubMedCrossRefGoogle Scholar
  12. 12.
    Partridge A, Adloff K, Blood E, et al. Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study. JNCI. 2008;100:243–51.PubMedGoogle Scholar
  13. 13.
    Black WC, Nease RF, Tosteson ANA. Perception of breast cancer risk and screening effectiveness in women younger than 50 years of age. JNCI. 1995;87:720–31.PubMedGoogle Scholar
  14. 14.
    Alexander NE, Ross J, Sumner W, Nease RF, Littenberg B. The effect of an educational intervention on the perceived risk of breast cancer. J Gen Intern Med. 1996;11:92–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Quillin JM, McClish DK, Jones RM, et al. Duration of an intervention’s impact on perceived breast cancer risk. Health Educ Behav. 2008;35:855–65.PubMedCrossRefGoogle Scholar
  16. 16.
    Altschuler A, Nekhlyudov L, Rolnick SJ, et al. Positive, negative, and disparate-women’s differing long-term psychosocial experiences of bilateral or contralateral prophylactic mastectomy. Breast J. 2008;14:25–32.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2011

Authors and Affiliations

  • Andrea Abbott
    • 1
  • Natasha Rueth
    • 1
  • Susan Pappas-Varco
    • 1
  • Karen Kuntz
    • 2
  • Elizabeth Kerr
    • 1
  • Todd Tuttle
    • 1
  1. 1.Department of SurgeryUniversity of MinnesotaMinneapolisUSA
  2. 2.Division of Health Policy and Management, School of Public HealthUniversity of MinnesotaMinneapolisUSA

Personalised recommendations